Oral Medication | Page 3 of 11

Invokana Helps My Type 1 Diabetes

I emailed my endo ahead of time to give her a heads up that I wanted to discuss going on Invokana. Unfortunately, she wasn't familiar with use of Invokana in Type 1 diabetes, or how insulin should be adjusted when on it. I sent her all of the research articles I could find related to Type 2 therapies being explored for Type 1. Luckily for me, and much to her credit, she was willing to prescribe it to me off label to give it a try.

Using Type 2 Medication to Treat Type 1 Diabetes

Using Type 2 Diabetes Medication to Treat Type 1 Diabetes

There have been a number of new developments in the treatment of type 2 diabetes, and a question often asked is whether some of the type 2 therapies might be beneficial for people with type 1 diabetes. For example, several years ago, one of my patients with type 1 diabetes was having trouble with weight and with blood glucose control on a basal-bolus insulin combination. We added metformin, and his blood sugars appeared to get a bit better.

FDA Issues Complete Response Letter for Type 2 Diabetes Drug Empagliflozin

The FDA has issued a complete response letter to Boehringer Ingelheim and Eli Lilly for the New Drug Application (NDA) of the investigational sodium glucose co-transporter-2 (SGLT2) inhibitor empagliflozin. The complete response letter referenced previously observed deficiencies at a Boehringer Ingelheim facility where empagliflozin will be manufactured.

Type 2 Diabetes Treatments May Benefit People with Type 1 Diabetes

The change in thinking about the ways type 2 diabetes evolves indirectly opened the door to considering new ways of thinking about how type 1 diabetes behaves. That shift led to considering whether that door swung both ways and if type 1 diabetics might benefit from treatments designed to treat type 2 diabetes.

FDA to Review Data Regarding Saxagliptin Use and Increased Risk of Heart Failure

The FDA has requested clinical trial data from the manufacturer of saxagliptin, Bristol-Myers Squibb and AstraZeneca, to investigate a possible association between use of the type 2 diabetes drug and heart failure.

FDA Approves Farxiga, AstraZeneca and Bristol-Myers Squib New Type 2 Diabetes Treatment

The U.S. Food and Drug Administration (FDA) has approved AstraZeneca and Bristol-Myers Squib new type 2 diabetes treatment, Farxiga (dapagliflozin), a once-daily oral treatment indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes.

FDA Advisory Committee Votes In Favor of NewType 2 Diabetes Drug, Dapagliflozin.

The FDA's Endocrinologic and Metabolic Drugs Advisory Committee (EMDAC) has decided (13-1) in favor of Bristol-Myers Squib and AstraZeneca's type 2 diabetes drug, dapagliflozin. The committeee found that the benefits of dapagliflozin use outweigh identified risks and support marketing of dapagliflozin as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.

Avandia Restriction Lifted by FDA

The U.S. FDA has lifted certain restrictions on prescribing and use of the diabetes drug Avandia (rosiglitazone) to reflect new information regarding the cardiovascular risk of the medicine.

Volunteers Needed for NIH Diabetes Study

If you've been diagnosed with type 2 diabetes in the last 5 years, you may be eligible to help scientists test treatments by participating in an NIH study. NIH has launched a long-term clinical trial called the GRADE study. Researchers will examine the benefits and risks of common diabetes drugs used with metformin.

BMS Presents Study Results for Type 2 Diabetes Drug Onglyza (saxagliptin)

AstraZeneca and Bristol-Myers Squibb have announced the full results of the SAVOR clinical trial of Onglyza (saxagliptin) in 16,492 adult patients with type 2 diabetes at high risk for cardiovascular events.